Cocrystal Pharma (COCP) Expected to Announce Earnings on Monday

Cocrystal Pharma (NASDAQ:COCP) is anticipated to issue its results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter.

Cocrystal Pharma Stock Performance

NASDAQ:COCP opened at $1.03 on Monday. The stock’s 50-day simple moving average is $1.02 and its 200 day simple moving average is $1.09. The company has a market cap of $14.19 million, a P/E ratio of -1.10 and a beta of 1.18. Cocrystal Pharma has a 52-week low of $0.86 and a 52-week high of $2.67.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cocrystal Pharma in a research note on Monday, December 22nd. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $6.00.

Insider Buying and Selling

In other news, Director Phillip Md Et Al Frost acquired 50,000 shares of the firm’s stock in a transaction dated Friday, February 6th. The stock was bought at an average price of $0.95 per share, with a total value of $47,500.00. Following the transaction, the director directly owned 1,888,551 shares in the company, valued at approximately $1,794,123.45. The trade was a 2.72% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders have acquired a total of 185,000 shares of company stock valued at $177,450 in the last ninety days. Company insiders own 28.14% of the company’s stock.

Institutional Investors Weigh In On Cocrystal Pharma

A hedge fund recently bought a new stake in Cocrystal Pharma stock. DRW Securities LLC purchased a new position in shares of Cocrystal Pharma, Inc. (NASDAQ:COCP) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned 0.24% of Cocrystal Pharma as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 6.72% of the company’s stock.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.